Study on T Cell Receptor Alpha/Beta Depletion Stem Cell Transplant for Blood Cancers

Sponsor: Masonic Cancer Center, University of Minnesota

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT05735717

Provider View

This clinical trial is testing a new type of stem cell transplant that removes certain immune cells to treat children and adults with blood cancers. The study aims to see if this approach is safe and effective.

Patient Parameters

Program Overview

This study is exploring a new method of stem cell transplantation for treating blood cancers in children and adults. The process involves removing specific immune cells, known as T cell receptor alpha/beta cells, from the stem cell transplant. The goal is to determine if this method is safe and can help treat various blood cancers, such as leukemia and myelodysplasia.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with a blood cancer, such as leukemia or myelodysplasia.
  • Specific types of leukemia, including Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).
  • Myelodysplasia with certain risk factors, like severe anemia or high-risk genetic features.
  • Aged 60 years or younger.
  • In good general health, with a performance status score of 70% or higher for adults, or a play score of 50% or higher for children under 16.
  • Have adequate organ function.

Exclusion Criteria

  • Pregnant or breastfeeding.
  • Have an active, uncontrolled infection within one week before starting treatment.
  • Tested positive for HIV or have active Hepatitis B or C with detectable virus levels.
  • Have had a previous stem cell transplant.
  • In a blast crisis phase of Chronic Myeloid Leukemia (CML).
  • Have an active cancer in the central nervous system.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.